BCLS II Equity Opportunities, LP 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:24 pm Purchase | 2024-09-30 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,750,151 11.000% | 343 (+0.01%) | Filing |
| 2024-02-13 6:59 pm Purchase | 2023-12-31 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,749,808 11.000% | 625,114 (+29.42%) | Filing |
| 2023-02-14 06:15 am Sale | 2022-12-31 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,124,694 11.000% | -4,139,726 (-66.08%) | Filing |